Nikolai V Gourine
10 Feb 2022
Afferent Medical Solutions' SCRATCH-HTN trial, assessing the efficacy of auricular sensory stimulation for uncontrolled hypertension, secures MHRA approval, signaling a pivotal milestone in hypertension treatment innovation.
Afferent Medical Solutions proudly announces that the SCRATCH-HTN Phase II sham-controlled randomized control trial has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA). This milestone signifies a significant step forward in evaluating the safety, acceptability, and efficacy of autonomic neuromodulation using transcutaneous auricular sensory stimulation in uncontrolled hypertensive patients.
MHRA approval validates the rigorous standards and scientific integrity of the SCRATCH-HTN trial, underscoring Afferent's commitment to advancing innovative solutions for hypertension management.
For media inquiries or further information, please contact:
Nikolai V Gourine
AFFERENT MEDICAL SOLUTIONS
c/o Clockwise, Brunel House,
2 Fitzalan Road,
Cardiff, Wales,
CF24 0EB
MENU
SOCIALS
© 2020 Afferent Medical Solutions Ltd. All rights Reserved